Related Experiment Video
Updated: May 24, 2026

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
In vivo CAR-T therapy: latest updates from the 2025 ASH annual meeting
Shule Wang1, Ran Kong1, Guangcai Zhong1
1Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, No. 324, Jingwu Road, Jinan, Shandong, 250021, China.
In vivo CAR-T therapy offers a simpler, more accessible alternative to traditional CAR-T cell treatments for blood cancers. This approach bypasses complex manufacturing, potentially reducing costs and timelines.
Area of Science:
- Oncology
- Immunotherapy
- Gene Therapy
Background:
- Chimeric antigen receptor (CAR)-T cell therapy shows promise for hematologic malignancies.
- Current CAR-T therapy involves complex ex vivo manufacturing and lymphodepleting chemotherapy.
More Related Videos
Related Concept Videos
Treatment Resistent Cancers
Treatment Resistant Cancers
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Gene Therapy
Gene Therapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

